Shares of Astrazeneca PLC (LON: AZN) slipped around 1% on Friday despite the approval that its Imfinzi drug received from the regulators in Japan.
Imfinzi, the immunotherapy treatment, is one of the best-selling drugs produced by the pharma giant, having generated $954 million in the first half of the year.
“This approval of Imfinzi provides an important new immunotherapy option in Japan for patients with extensive-stage small cell lung cancer,” Dave Fredrickson, AstraZeneca’’s executive VP for oncology said.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
“These patients have an especially poor prognosis, with only two per cent surviving beyond five years. Imfinzi, in combination with chemotherapy, delivers a sustained survival benefit and prolonged treatment response with a convenient dosing regimen given every four weeks during maintenance.”
Results from trials show that Imfinzi and chemotherapy treatment decreased the risk of death by 27% when compared with the chemotherapy treatment alone.
- Explore stock trading strategies
- Learn from experts on risk management in trading